5.1 Percentage of patients with acute coronary syndrome that are prescribed appropriate medicines at discharge

Purpose

This indicator addresses the effectiveness of processes that promote appropriate pharmacotherapy for secondary prevention of acute coronary syndromes.

Background and evidence

There is high level evidence supporting the use of anti-platelet agents, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II receptor antagonists (ARAs), beta-blockers and statins for secondary prevention of coronary heart disease.1-5 Indicators of appropriate management of acute coronary syndromes (ACS) have previously been used in Australian hospitals6-8 and general practice.9 Improving management of patients with ACS, including appropriate ongoing medication management, has been associated with reduced mortality.2,10 However, despite widespread evidence, many patients admitted with ACS are not discharged on appropriate medicines.6,11,12 Ensuring appropriate medication management after discharge is a guiding principle of the Australian Pharmaceutical Advisory Council Guiding Principles to Achieve Continuity in Medication Management.13 This indicator provides a measure of compliance with these guidelines.

Key definitions

**Acute coronary syndrome** refers to the following groups of conditions:1
- ST-segment-elevation myocardial infarction (STEMI)
- Non-ST-segment-elevation acute coronary syndrome (NSTEMI)
- Unstable angina pectoris (UAP)

If one or more of these medicine classes is not prescribed for the patient on discharge then the medication regimen can only be deemed as “appropriate” if there is a documented reason in the patient’s discharge summary for omission of that class of medicine, such as a contraindication, allergy or a documented plan to initiate that class of medicine in the future.

**Appropriate medicines** means the patient is discharged on one (or more) of the medicines from each of the four classes of medicines shown in Table 1.2,14,15

**At discharge** means there is documentation in the discharge summary or letter at time of transfer to community, residential care or other hospital that these medicines are to be taken on an ongoing basis. A supply of the medicines may or may not be dispensed by the hospital.
### Table 1. Appropriate medicines: medicine classes and examples

<table>
<thead>
<tr>
<th>Medicine class</th>
<th>Examples of suitable medicines available in Australia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-platelet agents</td>
<td>aspirin, clopidogrel, prasugrel, ticagrelor</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>atenolol, metoprolol, propranolol</td>
</tr>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td>in patients with left ventricular systolic dysfunction: carvedilol, bisoprolol, metoprolol (controlled release), nebivolol</td>
</tr>
<tr>
<td>ACEIs* OR ARAs*, **</td>
<td>captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril</td>
</tr>
<tr>
<td>OR</td>
<td>candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan</td>
</tr>
<tr>
<td>Statins</td>
<td>atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin</td>
</tr>
</tbody>
</table>

* Not all agents have been studied in post-ACS patients. However the clinical effects of the agents within each medicine class are generally considered to be similar and ACS guidelines do not distinguish between specific ACEIs or specific ARAs. However there may be variations in approved (licensed) indications in Australia.\(^{1,5,14,15}\)

** Guidelines recommend use of ARAs in patients who are intolerant of ACEIs.\(^{1-5}\)

### Data collection for local use

Please refer to the section *Using the National Quality Use of Medicines Indicators for Australian Hospitals* for guidance on sample selection, sample size, measurement frequency and other considerations.

**Inclusion criteria:** Patients aged 18 years or over with a principle diagnosis of ACS.

**Exclusion criteria:** Patients receiving clinical trial medicines, patients discharged against medical advice and patients receiving palliative/end of life care.

**Recommended data sources:** Discharge referral documentation.

The data collection tool for QUM Indicator 5.1 assists data collection and indicator calculation.

### Data collection for inter-hospital comparison

This indicator may be suitable for inter-hospital comparison. In this case, definitions, sampling methods and guidelines for audit and reporting need to be agreed in advance in consultation with the coordinating agency.

### Indicator calculation

\[
\frac{\text{Numerator}}{\text{Denominator}} \times 100\%
\]

**Numerator** = Number of patients with ACS who are prescribed appropriate medicines at discharge

**Denominator** = Number of patients with ACS in sample
Limitations and interpretation

This indicator looks at a bundle of care, not individual medicines. However it is recommended that individual components of the indicator are also collected to inform post-audit interventions. It may also be informative to look at data for each diagnosis separately (STEMI, NSTEMEACS or UAP).

Evidence-based guidelines recognise the importance of dual anti-platelet therapy (DAPT) in the management of STEMI and NSTEMEACS patients, as well as patients who have received percutaneous coronary intervention (PCI). Consideration should be given to auditing the use of DAPT in these patient groups, as well as assessing documentation of the recommended duration of DAPT to ongoing care providers at discharge.

The indicator does not take into consideration evidence-based dosing of the individual medicines.

This indicator excludes patients with ACS who presented to the emergency department with UAP but were not admitted. Nevertheless, the need for appropriate ongoing medication management for these patients should not be neglected.

Further information

The Discharge Management of Acute Coronary Syndrome (DMACS) Toolkit published by NPS MedicineWise is a quality improvement tool to assist hospital staff to conduct audits of the discharge management of patients with ACS. The toolkit, including audit tool and educational resources, is available at www.nps.org.au/health-professionals/cpd/activities/due-for-hospitals/discharge-management-of-acute-coronary-syndromes/dmacs-due/

Medication Safety Self Assessment for Australian Hospitals (MSSA) can help identify potential strategies for improvement with this and other indicators. MSSA encourages development of robust systems for safe prescribing, dispensing, administration and monitoring of medicines. MSSA is available at www.cec.health.nsw.gov.au

This indicator can be used to assist hospitals in meeting the National Safety and Quality Health Service Standard 1 [items 1.2.1, 1.2.2, 1.5.2, 1.6.1, 1.6.2, 1.7.2] and Standard 4 [items 4.1.2, 4.2.2, 4.5.1, 4.5.2, 4.12.4].

References

15. eTG complete [Internet]. Melbourne: Therapeutic Guidelines Ltd; 2012 February.